Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, announced today that Theresa Heggie, Chief Executive Officer, will present a company overview at the following virtual investor conferences in March:
- C. Wainwright Global Life Sciences Conference on March 9, 2021, available on-demand beginning at 7.00 a.m. ET
- Barclays Global Healthcare Conference on March 10, 2021, at 7:30 a.m. ET
The Company presentations from both conferences will be available on the investor relations section of the Freeline website at Freeline.life. Senior management will also participate in virtual one-on-one meetings with investors at these conferences.
